{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+400+mg&page=9",
    "query": {
      "intervention": "Placebo 400 mg",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 1035,
    "total_pages": 104,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+400+mg&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+400+mg&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T18:28:43.775Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01118273",
      "title": "Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Sleep"
      ],
      "interventions": [
        {
          "name": "Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg",
          "type": "DRUG"
        },
        {
          "name": "Naproxen Sodium 440 mg (BAYH6689)",
          "type": "DRUG"
        },
        {
          "name": "Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg",
          "type": "DRUG"
        },
        {
          "name": "Naproxen Sodium 220 mg (BAYH6689)",
          "type": "DRUG"
        },
        {
          "name": "DPH 50mg",
          "type": "DRUG"
        },
        {
          "name": "Ibuprofen 400 mg / Diphenhydramine citrate 76 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "16 Years to 45 Years"
      },
      "enrollment_count": 162,
      "start_date": "2008-01",
      "completion_date": "2008-02",
      "has_results": true,
      "last_update_posted_date": "2015-06-08",
      "last_synced_at": "2026-10-10T18:28:43.775Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01118273"
    },
    {
      "nct_id": "NCT01094483",
      "title": "A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Platelet Inhibition"
      ],
      "interventions": [
        {
          "name": "PN400",
          "type": "DRUG"
        },
        {
          "name": "ASA",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "50 Years to 75 Years"
      },
      "enrollment_count": 40,
      "start_date": "2010-03",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2010-12-07",
      "last_synced_at": "2026-10-10T18:28:43.775Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01094483"
    },
    {
      "nct_id": "NCT00981201",
      "title": "Celecoxib as a Chemopreventive Agent in Current and Former Smokers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Smoking",
        "Prevention"
      ],
      "interventions": [
        {
          "name": "Celecoxib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 219,
      "start_date": "2001-11",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2012-08-01",
      "last_synced_at": "2026-10-10T18:28:43.775Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00981201"
    },
    {
      "nct_id": "NCT03771612",
      "title": "Inflammation and Daily Life Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Inflammation"
      ],
      "interventions": [
        {
          "name": "Naproxen",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "45 Years to 60 Years"
      },
      "enrollment_count": 144,
      "start_date": "2022-02-09",
      "completion_date": "2024-06-21",
      "has_results": true,
      "last_update_posted_date": "2025-02-25",
      "last_synced_at": "2026-10-10T18:28:43.775Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03771612"
    },
    {
      "nct_id": "NCT05293171",
      "title": "Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "1.25 mg/kg BL-8040 + BL-8040-matching placebo",
          "type": "DRUG"
        },
        {
          "name": "2 mg/kg BL-8040",
          "type": "DRUG"
        },
        {
          "name": "BL-8040-matching placebo",
          "type": "DRUG"
        },
        {
          "name": "400 mg Moxifloxacin (1x400 mg tablet)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioLineRx, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 38,
      "start_date": "2021-06-11",
      "completion_date": "2022-08-15",
      "has_results": true,
      "last_update_posted_date": "2025-03-21",
      "last_synced_at": "2026-10-10T18:28:43.775Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05293171"
    },
    {
      "nct_id": "NCT01215292",
      "title": "ITT4 Intratesticular Hormonal Milieu in Man (ITT4)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Healthy Males"
      ],
      "interventions": [
        {
          "name": "Acyline",
          "type": "DRUG"
        },
        {
          "name": "Testosterone gel",
          "type": "DRUG"
        },
        {
          "name": "ketoconazole 400",
          "type": "DRUG"
        },
        {
          "name": "Ketoconazole 800",
          "type": "DRUG"
        },
        {
          "name": "Dutasteride",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Placebo ketoconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "18 Years to 50 Years · Male only"
      },
      "enrollment_count": 46,
      "start_date": "2011-01",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2014-03-31",
      "last_synced_at": "2026-10-10T18:28:43.775Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01215292"
    },
    {
      "nct_id": "NCT01658436",
      "title": "BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Neuroendocrine Tumors (pNET)"
      ],
      "interventions": [
        {
          "name": "BEZ235 (Stage 1)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2012-11",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2016-05-02",
      "last_synced_at": "2026-10-10T18:28:43.775Z",
      "location_count": 4,
      "location_summary": "Indianapolis, Indiana • Boston, Massachusetts • The Bronx, New York + 1 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01658436"
    },
    {
      "nct_id": "NCT01126970",
      "title": "Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Velneperit 400 mg",
          "type": "DRUG"
        },
        {
          "name": "Orlistat 120 mg",
          "type": "DRUG"
        },
        {
          "name": "Orlistat Placebo",
          "type": "DRUG"
        },
        {
          "name": "Velneperit Placebo",
          "type": "DRUG"
        },
        {
          "name": "Reduced Calorie Diet",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Shionogi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 486,
      "start_date": "2010-04",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2018-05-09",
      "last_synced_at": "2026-10-10T18:28:43.775Z",
      "location_count": 25,
      "location_summary": "Santa Rosa, California • Waterbury, Connecticut • Clearwater, Florida + 22 more",
      "locations": [
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01126970"
    },
    {
      "nct_id": "NCT02785770",
      "title": "A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PF-04447943",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 44,
      "start_date": "2016-06-29",
      "completion_date": "2016-10-20",
      "has_results": true,
      "last_update_posted_date": "2018-12-28",
      "last_synced_at": "2026-10-10T18:28:43.775Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02785770"
    },
    {
      "nct_id": "NCT02819856",
      "title": "SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ototoxicity"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "SPI-1005 Ebselen 200mg Capsule x1",
          "type": "DRUG"
        },
        {
          "name": "SPI-1005 Ebselen 200mg Capsule x2",
          "type": "DRUG"
        },
        {
          "name": "SPI-1005 Ebselen 200mg Capsule x3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sound Pharmaceuticals, Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2017-07-21",
      "completion_date": "2023-04-07",
      "has_results": true,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-10-10T18:28:43.775Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02819856"
    }
  ]
}